Clinical Trials Logo
  1. Home
  2. Covid19
  3. NCT04867174
  4. Details
NCT04867174 Clinical Trial

COVID-19 Vaccination Take-Up

Covid19 Clinical Trial

Official title:
COVID-19 Vaccination Take-Up in a County-Run Medicaid Managed Care Population

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT04867174
Other study ID # 27165
Secondary ID P30AG034532
Status Completed
Phase N/A
First received
Last updated
Start date May 24, 2021
Est. completion date May 24, 2022

Study information
Verified date March 2024
Source National Bureau of Economic Research, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In this work, the investigators are partnering with Contra Costa Health Services (CCHS), the department of health in Contra Costa County, CA, to measure COVID-19 vaccinations and other COVID-19 related preventive health behaviors in the county's Medicaid managed care population. This work will test ways to increase COVID-19 vaccine uptake. The investigators hypothesize that small financial incentives and other low-cost behavioral nudges can be used to increase vaccine uptake and reduce disparities in uptake among diverse racial/ethnic minority populations.

Recruitment information / eligibility
Status Completed
Enrollment 2701
Est. completion date May 24, 2022
Est. primary completion date August 15, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - age 18 and over - member of Contra Costa Health Plan (CCHP) Exclusion Criteria: - contraindications to vaccination, as determined by county health plan or other medical staff.

Study Design

Related Conditions & MeSH terms

Intervention

Behavioral:
• Financial incentives
Each of the study arms, including the no message/control arm, will be interacted with different financial incentives (N=5,000)
• Convenient scheduling link
In addition, study arms will be randomly assigned a convenient link to the county public vaccine appointment scheduling system highlighted for participants (N=5,000).
• Race concordant
Randomized to a messenger who is race concordant with the participant
• Gender concordant
Randomized to a messenger who is gender concordant with the participant

Locations
Country Name City State
United States Contra Costa Health Plan Martinez California

Sponsors (5)
Lead Sponsor Collaborator
National Bureau of Economic Research, Inc. Abdul Latif Jameel Poverty Action Lab, Contra Costa Health Services, National Institute on Aging (NIA), University of Southern California

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Other Vaccine Intentions Stated intention of receiving COVID-19 vaccination in the next 30 days (0% - 100% probability) 30 days
Primary Rate of COVID-19 Vaccination at 1 Month Percent of the population with at least one COVID-19 vaccination 1 month
See also
  Status Clinical Trial Phase
Completed NCT05047692 - Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers Phase 1
Recruiting NCT04395768 - International ALLIANCE Study of Therapies to Prevent Progression of COVID-19 Phase 2
Completed NCT04506268 - COVID-19 SAFE Enrollment N/A
Terminated NCT04555096 - A Trial of GC4419 in Patients With Critical Illness Due to COVID-19 Phase 2
Completed NCT04508777 - COVID SAFE: COVID-19 Screening Assessment for Exposure
Completed NCT04961541 - Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine Phase 1/Phase 2
Active, not recruiting NCT04546737 - Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients N/A
Not yet recruiting NCT04543006 - Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19 N/A
Completed NCT04532294 - Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants Phase 1
Terminated NCT04542993 - Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy Phase 2
Completed NCT04494646 - BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19) Phase 2
Terminated NCT04581915 - PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19 Phase 2/Phase 3
Completed NCT04537663 - Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults Phase 4
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT04387292 - Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic N/A
Not yet recruiting NCT04527211 - Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel Phase 3
Not yet recruiting NCT05038449 - Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19 N/A
Completed NCT04979858 - Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask N/A
Completed NCT04610502 - Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients Phase 2
Recruiting NCT06042855 - ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin) Phase 3